Anavex Presents 31-Week Safety Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer’s Patients at AAIC 2016
Date : 07/24/2016 @ 9:30AM
Source : GlobeNewswire Inc.
Stock : Anavex Life Sciences Corp. (MM) (AVXL)
Quote : 6.86 -0.25 (-3.52%) @ 8:00PM
Anavex Presents 31-Week Safety Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer’s Patients at AAIC 2016
Print
Anavex Life Sciences Corp. (NASDAQ:AVXL)
Intraday Stock Chart
Today : Sunday 24 July 2016
Click Here for more Anavex Life Sciences Corp. Charts.
Results Feature Favorable Safety, Maximum Tolerated Dose, Positive Dose Response as well as Positive Unexpected Therapeutic Response Events
Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced data from the first of two posters at the Alzheimer’s Association International Conference® (AAIC) 2016.
Data presented in the first poster highlights the evaluation of a maximum tolerated dose (MTD) of ANAVEX 2-73 as primary endpoint of the Phase 2a study in mild-to-moderate Alzheimer’s patients, as well as additional clinical safety data and positive unexpected therapeutic response events, such as improved mood, improved social engagement and increased independent activities through 31 weeks. The second poster will present efficacy data through 31 weeks.
“ANAVEX 2-73 data presented today is prerequisite information in order to progress into Phase 2/3 placebo controlled studies,” said Professor Harald Hampel, MD, PhD, Professor and AXA Research Fund Chair at Sorbonne Universities’ Pierre and Marie Curie University (UPMC), Paris, France and member of Anavex’s Scientific Advisory Board. “ANAVEX 2-73’s specific molecular biology, combined with its observed favorable safety and tolerability profile makes it a very interesting candidate to explore in further clinical trials of different neurological diseases.”
Dose-response analysis indicates a cognitive benefit associated with ANAVEX 2-73 (both MMSE and EEG/ERP improved significantly at 5 weeks of treatment). Low-High dose was statistically significant to affect MMSE-? and ERP-? scores with MMSE-? (p=0.0285) and ERP-? (p=0.0168), respectively.
ANAVEX 2-73 continues to demonstrate a favorable adverse event (AE) profile through 31 weeks in a patient population of elderly Alzheimer’s patients with varying degrees of physical fragility. The most common side effects across all AE categories tended to be of mild severity grade 1, and were resolved with dose reductions that were anticipated within the adaptive design of the study protocol. The poster presentation is available on the publications page of the Anavex website.
“We are encouraged by these new results, which provide us with valuable knowledge about ANAVEX 2-73 and allow us to proceed methodically in the development of ANAVEX 2-73,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex.
About the ANAVEX 2-73 Phase 2a Study
The multi-center Phase 2a clinical trial of 32 mild-to-moderate Alzheimer’s patients consists of two parts. In PART A ANAVEX 2-73 is administered during five weeks in a randomized, open-label study with adaptive design. PART B is continued administration of ANAVEX 2-73 in a voluntary 52-week open-label extension, followed by an additional voluntary 104-week extension study, allowing for the gathering of safety data for ANAVEX 2-73 cumulatively over three years.
The primary endpoint of the Phase 2a trial is to establish safety, tolerability and maximum tolerated dose (MTD) of ANAVEX 2-73. Secondary endpoints includes exploratory cognitive as well as functional measures using Mini Mental State Examination (MMSE) and evaluation of Alzheimer’s Disease Co-operative Study - Activities of Daily Living Inventory (ADCS-ADL), respectively.
Additional information regarding the ongoing Phase 2a clinical study is available from the U.S. National Institutes of Health (NIH) clinical trials database at www.clinicaltrials.gov.
